Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1066 to 1069 of 1069 results for drug therapy

  1. Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants (HTG276)

    Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).

    HealthTech guidance
    Published
    23 November 2011
    View recommendations

    Sections for HTG276

  2. Photodynamic therapy for Barrett's oesophagus (HTG223)

    Evidence-based recommendations on photodynamic therapy for Barrett's oesophagus. This involves using a light-activated drug (called a photosensitising agent) with a laser to destroy the abnormal cells and to promote the growth of healthy cells.

    HealthTech guidance
    Published
    23 June 2010
    View recommendations

    Sections for HTG223

  3. NICE says new triple negative advanced breast cancer drug too expensive for NHS use

    NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.

    News
    Last updated
    18 January 2024

  4. NICE approves routine use of drug combination for advanced breast cancer

    A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.

    News
    Last updated
    18 January 2024